Patents by Inventor Martin J. Borrok III

Martin J. Borrok III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Binding molecules specific for ASCT2 and uses thereof
    Patent number: 11608375
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: March 21, 2023
    Assignee: MedImmune, LLC
    Inventors: Nabendu Pore, Martin J. Borrok, III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury
  • BINDING MOLECULES SPECIFIC FOR ASCT2 AND USES THEREOF
    Publication number: 20210024629
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Inventors: Nabendu Pore, Martin J. Borrok III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury
  • Binding molecules specific for ASCT2 and uses thereof
    Patent number: 10829554
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: November 10, 2020
    Assignee: MedImmune, LLC
    Inventors: Nabendu Pore, Martin J. Borrok, III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury
  • Binding Molecules Specific For ASCT2 And Uses Thereof
    Publication number: 20190367605
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof, used in methods related to cancer stem cells, e.g., binding to a cancer stem cell. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates. In certain aspects, the ASCT2-binding molecules bind specifically to cancer stem cells expressing ASCT2.
    Type: Application
    Filed: November 8, 2017
    Publication date: December 5, 2019
    Inventors: Nabendu Pore, Martin J. Borrok III, Partha S. Chowdhury, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Elaine M. Hunt, Nai Shun Yao
  • BINDING MOLECULES SPECIFIC FOR ASCT2 AND USES THEREOF
    Publication number: 20180273617
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
    Type: Application
    Filed: November 10, 2016
    Publication date: September 27, 2018
    Inventors: Nabendu Pore, Martin J. Borrok III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury